Consistent with these reports, we found that LAT1 knockdown increased oxaliplatin sensitivity and high membrane LAT1 expression was an independent predictor for poor survival and recurrence in CRC patients receiving an adjuvant CAPOX regimen, but not in our adjuvant UFT + LV and capecitabine groups. This evidence concerns the gene SLC7A5 and colorectal carcinoma.